A preliminary study to identify existing drugs for potential repurposing in breast cancer based on side effect profile

Abstract

Breast cancer is the most commonly diagnosed cancer and the second leading cause of cancer-related death in women after lung cancer. The present study aims to identify potential drug candidates using the PROMISCUOUS database for breast cancer based on side effect profile and then proceed with in silico and in vitro studies. PROMISCUOUS database was used to construct a group of drugs that share maximum side effects with letrozole. Based on the existing literature, ropinirole, risperidone, pregabalin, and gabapentin were selected for in silico and in vitro studies. The molecular docking was carried out using AUTODOCK 4.2.6. MCF-7 cell line was used to evaluate the anti-cancer activity of the selected drugs. PROMISCUOUS database revealed that as many as 23 existing drugs shared between 62 and 79 side-effects with letrozole. From docking result, we found that, ropinirole showed a good binding affinity (−7.7 kcal/mol) against aromatase compared to letrozole (−7.1 kcal/mol) which was followed by gabapentin (−6.4 kcal/mol), pregabalin (−5.7 kcal/mol) and risperidone (−5.1 kcal/mol). From the in vitro results, ropinirole and risperidone showed good anti-cancer activity of IC₅₀ with 40.85±11.02 μg/ml and 43.10±9.58 μg/ml cell viability. Based on this study results and existing literature we conclude that risperidone, pregabalin, and gabapentin are not ideal candidates for repurposing in breast cancer but ropinirole could be an excellent choice for repurposing in breast cancer after further studies.

Key words

cancer - anticancer drugs - cancer pharmacology - drug research - pharmacology

Publikationsverlauf

Eingereicht: 13. Dezember 2022

Angenommen: 09. Januar 2023

Artikel online veröffentlicht:
06. März 2023

• References

• 1 Hassanpour SH, Dehghani M.. Review of cancer from perspective of molecular. J Cancer Res Pract 2017; 4: 127-129
• 2 Torre LA, Islami F, Siegel RL. et al. Global cancer in women: Burden and trends. Cancer Epidemiol Biomarkers Prev 2017; 26: 444-457
• 3 Sledge GW, Mamounas EP, Hortobagyi GN. et al. Past, present, and future challenges in breast cancer treatment. J Clin Oncol 2014; 32: 1979-1986
• 4 Hussain SA, Palmer DH, Stevens A. et al. Role of chemotherapy in breast cancer. Expert Rev Anticancer Ther 2005; 5: 1095-1110
• 5 Rudrapal M J, Khairnar S G, Jadhav A.. Drug Repurposing (DR): An Emerging Approach in Drug Discovery. Drug Repurposing – Hypothesis. Mol. Asp. Ther. Appl. 2020
• 6 Cha Y, Erez T, Reynolds IJ. et al. Drug repurposing from the perspective of pharmaceutical companies. Br J Pharmacol 2018; 175: 168-180
• 7 Campillos M, Kuhn M, Gavin AC. et al. Drug target identification using side-effect similarity. Science 2008; 321: 263-266
• 8 Von Eichborn J, Murgueitio MS, Dunkel M. et al. PROMISCUOUS: A database for network-based drug-repositioning. Nucleic Acids Res 2011; 39: D1060-D1066
• 9 Gallo K, Goede A, Eckert A. et al. PROMISCUOUS 2.0: A resource for drug-repositioning. Nucleic Acids Res 2021; 49: D1373-D1380
• 10 Oleg T, Arthur J.O.. AutoDock Vina: Improving the Speed and Accuracy of Docking with a New Scoring Function, Efficient Optimization, and Multithreading. J Comput Chem 2010; 31: 2967-2970
• 11 Bahuguna A, Khan I, Bajpai VK. et al. MTT assay to evaluate the cytotoxic potential of a drug. Bangladesh J Pharmacol 2017; 12: 115-118
• 12 Yang L, Agarwal P.. Systematic drug repositioning based on clinical side-effects. PLoS One 2011; 6: e28025
• 13 Chartier M, Morency LP, Zylber MI. et al. Large-scale detection of drug off-targets: Hypotheses for drug repurposing and understanding side-effects. BMC Pharmacol Toxicol 2017; 18: 1-6
• 14 Rubí B, Maechler P.. Minireview: New roles for peripheral dopamine on metabolic control and tumor growth: Let’s seek the balance. Endocrinology 2010; 151: 5570-5581
• 15 Borcherding DC, Tong W, Hugo ER. et al. Expression and therapeutic targeting of dopamine receptor-1 (D1R) in breast cancer. Oncogene 2016; 35: 3103-3113
• 16 Sarkar C, Chakroborty D, Chowdhury UR. et al. Dopamine increases the efficacy of anticancer drugs in breast and colon cancer preclinical models. Clin Cancer Res 2008; 14: 2502-2510
• 17 Pornour M, Ahangari G, Hejazi S. et al. New Perspective Therapy of Breast Cancer Based on Selective Dopamine Receptor D2 Agonist and Antagonist Effects on MCF-7 Cell Line. Recent Pat Anticancer Drug Discov 2015; 10: 214-223
• 18 Johnson DE, Ochieng J, Evans SL.. The growth inhibitory properties of a dopamine agonist (SKF 38393) on MCF-7 cells. Anticancer Drugs 1995; 6: 471-474
• 19 Wang PS, Walker AM, Tsuang MT. et al. Dopamine antagonists and the development of breast cancer. Arch Gen Psychiatry 2002; 59: 1147-1154
• 20 Pottegård A, Lash TL, Cronin-Fenton D. et al. Use of antipsychotics and risk of breast cancer: a Danish nationwide case–control study. Br J Clin Pharmacol 2018; 84: 2152-2161
• 21 Fernandez I, Touraine P, Goffin V.. Prolactin and human tumourogenesis. J Neuroendocrinol 2010; 22: 771-777
• 22 De Hert M, Peuskens J, Sabbe T. et al. Relationship between prolactin, breast cancer risk, and antipsychotics in patients with schizophrenia: A critical review. Acta Psychiatr Scand 2016; 133: 5-22
• 23 Reynolds C, Montone KT, Powell CM. et al. Expression of prolactin and its receptor in human breast carcinoma. Endocrinology 1997; 138: 5555-5560
• 24 Rai AS, Khan JS, Dhaliwal J. et al. Preoperative pregabalin or gabapentin for acute and chronic postoperative pain among patients undergoing breast cancer surgery: A systematic review and meta-analysis of randomized controlled trials. J Plast Reconstr Aesthetic Surg 2017; 70: 1317-1328